Company news

Immunic, Inc. news in 2021

Immunic, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

December 13, 2021

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

December 8, 2021

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

November 17, 2021

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

November 3, 2021

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update

October 31, 2021

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

October 27, 2021

Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935

October 26, 2021

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

October 13, 2021

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

September 29, 2021

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

September 21, 2021

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

August 5, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

July 18, 2021

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

July 14, 2021

Immunic, Inc. Announces Proposed Public Offering of Common Stock

July 13, 2021

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

July 11, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

June 30, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

May 31, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

May 5, 2021

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

April 14, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838

March 30, 2021

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

February 25, 2021

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

February 17, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

February 16, 2021

Immunic, Inc. to Participate in Investor Conferences in January

January 4, 2021

Calls in 2021

Decks in 2021